|1.||Nair, Venugopal: 2 articles (01/2009 - 08/2003)|
|2.||Coppo, Mauricio J C: 1 article (07/2012)|
|3.||Browning, Glenn F: 1 article (07/2012)|
|4.||Markham, John F: 1 article (07/2012)|
|5.||Devlin, Joanne M: 1 article (07/2012)|
|6.||Lee, Sang-Won: 1 article (07/2012)|
|7.||Hartley, Carol A: 1 article (07/2012)|
|8.||Legione, Alistair R: 1 article (07/2012)|
|9.||Ficorilli, Nino: 1 article (07/2012)|
|10.||Markham, Philip F: 1 article (07/2012)|
08/01/1994 - "The present results suggest that development of a vaccination procedure to stimulate the mucosal immune response should improve the protective effects of the inactivated herpesvirus vaccines, and thereby make it possible to control the infections by prohibiting virus replication at the site where primary infection takes place, as well as inhibiting subsequent latency and reactivation of the virus."
07/13/2012 - "This has raised safety concerns about using attenuated herpesvirus vaccines in human and veterinary medicine and adds to other known concerns associated with their use, including reversion to virulence and disease arising from recurrent reactivation of lifelong chronic infection. "
01/01/1978 - "An account is presented of the development and use of herpesvirus vaccines in domestic animals, with particular reference to those viruses causing cytolytic rather than oncogenic infections. "
|2.||Marek Disease (Marek's Disease)
01/07/2009 - "Live attenuated herpesvirus vaccines such as herpesvirus of turkey (HVT) have been used since 1970 for the control of Marek's disease (MD), a highly infectious lymphoproliferative disease of poultry. "
08/01/2003 - "Replication-competent bacterial artificial chromosomes of Marek's disease virus: novel tools for generation of molecularly defined herpesvirus vaccines."
02/01/1989 - "Our objective was to determine whether the cell-associated herpesvirus vaccines used in chickens to control Marek's disease tumors can augment development of lymphoid leukosis (LL) induced by exogenous avian leukosis virus (ALV). "
04/01/1986 - "Comparative 50% protective dose (PD50) assays were performed using a plaque-purified preparation of Marek's disease virus (MDV) strain CVI-988 at the 65th chicken embryo fibroblast (CEF) passage level (MDV CVI-988 CEF65 clone C) and three commercial MD vaccines: herpesvirus of turkeys (HVT) FC126, MDV CVI-988 CEF35, and a bivalent vaccine composed of HVT FC126 and MDV SB-1. "
|1.||ganhuangenin (Sb 1)